RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 10 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Has histologically confirmed locally advanced (Stage IIIB/C) or metastatic (Stage IV) non-squamous NSCLC

    Inclusion criterion 2

    Has KRAS G12C mutation confirmed by central laboratory

    Inclusion criterion 4

  3. Male and female subjects of reproductive potential must agree to use effective contraception during and for 6 months after treatment

    Inclusion criterion 10

    Prior treatment with KRAS G12C inhibitors, FAK inhibitors, or immune checkpoint inhibitors

    Exclusion criterion 3

  4. ECOG performance status of 0-1

    Inclusion criterion 7

  5. Has another known driver mutation with approved targeted therapy (e.g., EGFR, ALK, ROS1)

    Exclusion criterion 4

  6. Has at least one measurable lesion per RECIST v1.1

    Inclusion criterion 6

  7. Has history of another malignancy within 5 years, except those curatively treated and considered low risk (e.g., basal cell carcinoma, cervical carcinoma in situ)

    Exclusion criterion 6

    Has known active hepatitis B, hepatitis C, or HIV infection

    Exclusion criterion 8

  8. Pregnant or breastfeeding women

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07174908, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Able and willing to provide informed consent and comply with study requirements
  • Has histologically confirmed locally advanced (Stage IIIB/C) or metastatic (Stage IV) non-squamous NSCLC
  • Aged 18-80 years at the time of consent
  • Has KRAS G12C mutation confirmed by central laboratory
  • Has not received prior systemic therapy for advanced or metastatic NSCLC
  • Has at least one measurable lesion per RECIST v1.1
  • ECOG performance status of 0-1
  • Has adequate organ function
  • Life expectancy ≥3 months in the opinion of the Investigator
  • Male and female subjects of reproductive potential must agree to use effective contraception during and for 6 months after treatment

Exclusion Criteria:

  • Has other histological subtypes of NSCLC (e.g., small cell or neuroendocrine)
  • Has active or untreated CNS metastases or carcinomatous meningitis
  • Prior treatment with KRAS G12C inhibitors, FAK inhibitors, or immune checkpoint inhibitors
  • Has another known driver mutation with approved targeted therapy (e.g., EGFR, ALK, ROS1)
  • Has uncontrolled cardiovascular disease, active severe infection, interstitial lung disease, or autoimmune disease requiring systemic therapy
  • Has history of another malignancy within 5 years, except those curatively treated and considered low risk (e.g., basal cell carcinoma, cervical carcinoma in situ)
  • Has gastrointestinal conditions that may interfere with absorption of oral drugs (if applicable)
  • Has known active hepatitis B, hepatitis C, or HIV infection
  • Has received a live vaccine within 30 days before first dose of study drug
  • Pregnant or breastfeeding women
  • Has psychiatric or substance abuse disorders that would interfere with study compliance
  • Is participating in another interventional clinical study
  • Any condition that, in the opinion of the Investigator, would interfere with participation or study results

Quoted from ClinicalTrials.gov, NCT07174908, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07174908, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07174908